[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-liver-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,41,65,93,124,148,167,192,222,249,277,296,322,345,375,396,421,456],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644343","effect-of-ursodeoxycholic-acid-supplementation-on-liver-regeneration-in-adult-living-donor-liver-transplant-ldlt-recipients-100644343",false,"NCT07664020","Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration in Adult Living Donor Liver Transplant (LDLT) Recipients.","Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration in Adult Living Donor Liver Transplant (LDLT) Recipients : A Placebo Controlled Randomised Trial","Inclusion Criteria:\n\nAll Adult Living Donor Liver Transplant (LDLT) Recipients in ILBS from ethical board clearance to December 2027 in the Department of HPB Surgery and Liver Transplantation, Institute of Liver and Biliary Sciences\n\nExclusion Criteria:\n\n* Unwillingness to participate\n* Hypersensitivity to UDCA\n* Patients receiving UDCA pre-operatively within 1 month of liver transplant (PBC and patients of overlap syndrome)\n* Right posterior and left laterals grafts\n* Emergency Liver Transplant","ALL","18 Years","70 Years",{"count":20,"type":21},130,"ESTIMATED","INTERVENTIONAL",[24],"NA","This placebo controlled randomized control study aims to analyze the effect of UDCA supplementation on liver regeneration in Living Donor Liver Transplant (LDLT) recipients. All eligible LDLT recipients during the study period will be included in the study and randomized into two groups. One group will receive Tab UDCA starting atleast 10 days pre-operatively and continued till post-operative day 10 and the other group will receive placebo. UDCA will be given at a dose of 15mg\u002Fkg per day in two divided doses. Recipients who are not willing to participate in the study, have hypersensitivity to UDCA will be excluded from the study. Pediatrics recipients and acute liver failure recipients will also be excluded.\n\nPre- operative, intra-operative and post-operative data will be collected from medical records, electronic hospital information system (HIS) and radiological images collected from the hospital Picture archiving and communication system (PACS). The enrolled subjects will be followed up till for a period of 14 days after the transplant till NCCT Abdomen is done and regenerated liver volumes are analyzed. The anatomic(volumetric), functional(liver function tests) and regenerative biomarkers (HGF, TNF-Alpha, IL6, TGF-Beta1) will be compared between the two groups. Evaluation of incidence of Early Allograft Dysfunction (EAD) as per Modified Olthoff criteria1 will be done between the two groups. FXR receptor concentration (hepatocytes) and TGR-5 receptor concentration (cholangiocytes) will be seen in the explant liver along with evaluation of monocyte number and function and mitochondrial and nuclear DNA.",[27],"Chronic Liver Disease","NOT_YET_RECRUITING","2026-06-17",{"date":31,"type":32},"2026-06-23","ACTUAL",{"date":34,"type":21},"2026-06-18",{"date":36,"type":21},"2027-11-01",{"name":38,"class":39},"Institute of Liver and Biliary Sciences, India","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100545886","referral-of-patients-to-hepatology-with-hepatoscope-100545886","NCT06387745","Referral of Patients to Hepatology With Hepatoscope","Use of Ultrasound Tools to Refer Patients at Risk of Chronic Liver Disease to the Hepatology Consultation (US-REFERRAL)","US-REFERRAL","Inclusion Criteria:\n\n* Patients with any of the following\n\n  * Elevated liver enzymes (AST, ALT, Gamma-GT, AP)\n  * Type 2 diabetes\n  * Elements of metabolic syndrome\n* Patients who consent in written to participate in the Clinical Investigation after being orally informed on the objectives and methods of the Clinical Investigation\n\nExclusion Criteria:\n\n* Patients with active implants such as pacemakers, defibrillators, pumps, etc.\n* Patients presenting wounds at the location where the Hepatoscope probe shall be placed on patients' skin,\n* Pregnant and breastfeeding women,\n* People deprived of their freedom rights.","80 Years",{"count":51,"type":21},200,[24],"Patients identified as being at risk of liver fibrosis because of a positive Fibrosis-4 (FIB-4) test in the primary care setting will be offered be enrolled in the trial and to undergo an Hepatoscope exam (external non-invasive ultrasound imaging exam) to screen for liver fibrosis (with stiffness measurements) and\u002For steatosis (with ultrasound parameters related to fatty liver). All patients presenting with a liver stiffness value of at least 6.5 kilopascal (kPa) will be referred to the tertiary hepatology consultations for further assessment. Hepatoscope measurements will be compared to the standard of care for these patients, as defined at the tertiary hepatology center.",[27],"RECRUITING","2026-05-04",{"date":58,"type":32},"2026-05-08",{"date":60,"type":32},"2025-08-22",{"date":62,"type":21},"2026-12",{"name":64,"class":39},"University Hospital, Antwerp",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":40},"100629197","copper-supplementation-in-cirrhosis-100629197","NCT07471542","Copper Supplementation in Cirrhosis","A Pilot Randomized Controlled Trial to Determine the Biochemical Effect, Safety and Patient Reported Outcomes of Copper Supplementation in Patients With Cirrhosis","Inclusion Criteria:\n\n1. Adult patients age 18 or older with confirmed diagnosis of cirrhosis based on clinical history, exam, imaging, laboratory or histological criteria;\n2. Cirrhosis patients whose serum or plasma Cu are below the normal range (80-155 ug\u002FdL for women and 70-140 ug\u002FdL for men);\n3. Cirrhosis patients whose serum or plasma Cu are in the normal range but exhibit at least one clinical feature that has been associated with Cu deficiency. These include history of infections, unexplained anemia, severe leukopenia, iron overload, unexplained neurological symptoms such as ataxia or myelopathy, coagulopathy with spontaneous bleeding.\n\nPatients must meet inclusion criteria 1 AND 2, or 1 AND 3 in order to be considered for the trial\n\nExclusion Criteria:\n\n1. Patients with Wilson disease, cholestatic liver diseases including primary biliary cholangitis and primary sclerosing cholangitis, all of which are associated with Cu overload;\n2. Patients with fulminant hepatic failure;\n3. Renal failure with a creatinine clearance \\\u003C25 ml\u002Fminute;\n4. Hepatic encephalopathy more than grade 2 (Hepatic Encephalopathy in Chronic Liver Disease, 2014);\n5. MELD score \\>25 to minimize subject dropout due to been too ill;\n6. Serious non-liver related medical illnesses such as cardiopulmonary and renal diseases and non-liver malignancies;\n7. Active alcohol use;\n8. Pregnancy",{"count":73,"type":21},30,[24],"End stage liver disease or cirrhosis is a major cause of mortality in the United States and the world. Other than targeting the underlying cause, such as alcohol cessation and antiviral therapy, very few medical treatments can change the natural history of cirrhosis. Malnutrition is one of the few potentially modifiable factors that have been associated with cirrhosis severity and poor prognosis. The transition metal copper (Cu) is an essential trace metal that must be acquired from diet. Its metabolism is primarily regulated by the liver in its role as a master regulator of nutrients. In 2019, the investigators reported that Cu deficiency defined by below normal serum or liver concentrations occurred in a wide range of liver disorders and was associated with a severe disease phenotype. Improvement in liver function was observed in 2 of the 3 patients who received Cu supplementation. In 2023, the investigators conducted a longitudinal cohort study utilizing clinical, serum and liver explant tissue data from 183 cirrhosis patients. The investigators showed that Cu deficiency was associated with 2-fold higher infection rate and a more than 3-fold increase in the risk of death compared to patients with normal Cu status. These preliminary findings and the well-established importance of Cu in human health prompted the investigators to design the current pilot randomized, placebo-controlled, crossover trial to determine the effect of Cu supplementation on Cu dependent biochemical changes, patient safety and patient reported outcomes in cirrhosis.",[77,27,78,79],"Cirrhosis","Fibrosis","Infection",[81,82,83],"copper","cirrhosis","malnutrition","2026-03-10",{"date":86,"type":32},"2026-03-13",{"date":88,"type":21},"2026-03-15",{"date":90,"type":21},"2028-12",{"name":92,"class":39},"University of Washington",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":40},"100446613","fast-irm-for-hcc-surveillance-in-patients-with-high-risk-of-liver-cancer-100446613","NCT05095714","FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.","Randomized Study Evaluating the Cost Impact and Effectiveness of Systematic Liver Fast-MRI Surveillance for Early-stage Hepatocellular Carcinoma in High-risk Patients Included in Ultrasound Surveillance Programs","FASTRAK","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient enrolled in a screening program for at least 6 months in a tertiary hepatology center\n* Cirrhosis histologically proven or unequivocally suggested by non-invasive tests\n* Absence of HCC on imaging less than 3 months o\n* Liver parenchyma explorable by ultrasound\n* Child-Pugh A or B\n* Cirrhosis of non-viral or viral B\u002FC cause controlled\u002Fhealed\n* With an estimated annual risk of HCC\\>3%\n* Written informed consent\n* Affiliation to a social security system\n\nExclusion Criteria:\n\n* Child-Pugh C score\n* Active hepatitis B or C\n* Estimated annual risk of HCC\\\u003C3%\n* No prior enrollment in a screening program\n* Contraindication to Fast-MRI\n* Non-echogenic patient\n* Patient deprived of liberty\n* Patient under legal protection\n* Pregnant or breastfeeding woman\n* Patient on AME (state medical aid)",{"count":102,"type":21},944,[24],"Intro: Hepatocellular carcinoma (HCC) is the 6th leading cause of cancer worldwide. In France, more than 10,000 new cases are identified each year. The latter occur in 85% of cases in cirrhosis, the most frequent causes of which are excessive alcohol consumption, metabolic syndrome or HBV\u002FHCV infection. Patients with cirrhosis justify being included in monitoring programs involving the performance of a semi-annual liver ultrasound (US) in order to detect HCC eligible for curative treatment (liver resection or percutaneous ablation). This practice is considered to be cost-effective in the event of an annual incidence of HCC\\> 1.5%. US in this context has a low sensitivity for the detection of HCC at the very early stage and the following observations have been made in the last 20 years:\n\n* The rate of patients detected at early stage BCLC 0 is around 30% by ultrasound\n* The rate of patients included in surveillance programs detected with advanced HCC eligible for palliative treatment is around 20%\n* Reducing the periodicity of liver ultrasounds from 6 to 3 months does not improve these results.\n\nIn parallel, liver MRI has been evaluated as a tool for the early detection of HCC. Its performance for the detection of HCC at the very early stage exceeds 80%. However, due to the higher cost compared to US, it was estimated that its use in screening context would only be cost effective in the event of an annual incidence\\> 3%. In addition, the practice of these expensive and long-lasting MRIs (30 to 45 minutes) can be optimized by carrying out abbreviated MRI protocols\" or Fast-MRI: short protocols (\\\u003C10 minutes), based on the sequences with the better detection sensitivities (Se\\> 83%).\n\nThe hypothesis is that Fast-MRI used as a screening examination in patients at high risk of HCC (\\> 3% per year) could increase the rates of patients detected at an early stage accessible to curative treatment and demonstrate its cost-effectiveness in this population.\n\nHypothesis\u002FObjective: The main objective is to assess the cost \u002F QALY and \u002F patient detected with an early HCC BCLC 0 (single tumor \\\u003C2cm) by semi-annual monitoring by liver US and Fast-MRI, compared to conventional semi-annual monitoring by liver US alone in patients with cirrhosis and an anticipated HCC incidence\\>3%.\n\nConclusion: If positive, this trial could modify international practice guidelines and set MRI as the optimal tool for early HCC detection in high-risk patients.",[106,107,77,27],"Hepatocellular Carcinoma","Liver Cancer",[109,110,77,111,112,113,114,115],"Hepatocellular carcinoma","Liver cancer","Chronic liver disease","Surveillance","Detection","MRI","Risk stratification",{"date":117,"type":32},"2026-03-12",{"date":119,"type":32},"2022-11-23",{"date":121,"type":21},"2030-06-23",{"name":123,"class":39},"Assistance Publique - Hôpitaux de Paris",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":131,"maxAge":18,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":40},"100554031","phase-3-in-patients-with-chronic-liver-diseasesalcoholic-liver-disease-and-non-alcoholic-fatty-liver-disease-laennechuman-placenta-hydrolysate-is-to-evaluate-the-efficacy-and-safety-of-intravenous-drop-100554031","NCT06493799","In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop","A Multicenter, Randomized, Open-label, Active-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Drop of 'LAENNEC INJ. (Human Placenta Hydrolysate) Compared With Subcutaneous Injection in Patients With Chronic Liver Disease","Inclusion Criteria:\n\nA participant will be eligible for participation in the trial if all of the following inclusion criteria are met:\n\n1. At the time of screening, 19 or 70 years\n2. Those who have been diagnosed with alcoholic or non-alcoholic fatty liver disease\n3. Those who have increased ALT level (Increased ALT level : 60 IU\u002FL ≤ ALT ≤ 200 IU\u002FL)\n4. A person who can complete the signature agreement and comply with clinical trial requirements.\n\nExclusion Criteria:\n\nA participant will not be eligible for trial participation if any of the following exclusion criteria are met:\n\n1. If you have the following disease\n\n   * Liver cancer or other malignant tumor within 5 years at screening point\n   * Esophageal varix bleeding, hepatic coma, ascites etc. related disease or Child-Pugh Score Class B,C patient within 1 year at screening point\n   * Organs or bone marrow transplant experience\n   * Billiary atresia, Genetic metabolic liver disease, Fulminant Hepatic failure, toxicity or Clinically diagnosed hepatitis, bleeding or Platelet disease patient\n   * Autoimmune hepatitis, Primary biliary cirrhosis, Sclerosing cholangitis, IgG4- associated cholangitis patient\n   * Bariatric Surgery within 24 weeks at screening point\n   * Uncontrolled diabetes mellitus (HBA1c \\> 9.0%)\n   * Uncontrolled serious Cardiopulmonary disease\n   * Liver cancer or other malignant tumor within 5 years at screening point\n   * Those who have alcohol abuse within 5 years at screening point\n   * Hepatitis B, C virus (However, those who have been identified as HBV DNA undetectable or SVR after antiviral administration can participate)\n   * Systemic infection (including tuberculosis)\n2. If you are taking the following drug (Hepatotonics)\n\n   * However, it is possible to register after having a drug holiday\n\n     * Biphenyl dimethyl dicarboxylate (BDD), Silymarin(Milk thistle) : 14 days\n     * Ursodeoxycholic acid (UDCA) : 30 days\n     * Other Hepatotonics : 5 times half-life\n3. If you are taking the following drug or need to take drugs during the clinical trial period\n\n   * Antituberculous drug(Isoniazid, Rifampin etc.), antifungal agent and antibiotic\n   * Acetaminophen, NSAIDs(Excluding low-dose aspirin for preventive purposes)\n   * Lipid lowering agent(Niacin etc.) and Oral hypoglycemic agent(acarbose etc.) (Registered when administered during the clinical trial period with a certain dose without a change in dose currently being taken)\n   * Antiseric agent (ARB, Beta-blocker, CCB etc.) (Registered when administered during the clinical trial period with a certain dose without a change in dose currently being taken)\n   * Vitamin E (Purpose of treatment of more than 800 IU\u002Fday)\n   * Astrogens\n   * Systemic corticosteroids, Immunomodulator\n4. If you take more alcohol than the recommended amount (Man 40 g\u002Fday, Woman 20 g\u002Fday)\n5. Drug allergic symptoms (oscillation, heat, itching)\n6. Those who have received other clinical drugs within 4 weeks before selecting a test subject\n7. Those who cannot inject intravenous infusions (5% Dextrose Inj.)\n8. A person who does not perform appropriate contraception as a pregnant woman, a nursing or a woman of childbearing age (effective contraception method: Barrier methods using infertility surgery, uterine device, condom, killer)\n9. Those who judged that other testors were inappropriate as clinical trials","19 Years",{"count":133,"type":21},226,[135],"PHASE3","Control group : LAENNEC subcutaneous injection (4 ml)\n\nExperimental group : LAENNEC intravenous injection (10 ml)",[27],"2026-02-23",{"date":140,"type":32},"2026-02-25",{"date":142,"type":32},"2024-07-01",{"date":144,"type":21},"2026-09-30",{"name":146,"class":147},"Green Cross Wellbeing","INDUSTRY",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":154,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":40},"100613762","to-study-the-clinical-course-and-outcomes-of-non-electively-hospitalised-patients-of-chronic-liver-disease-cld-with-hepatic-or-extra-hepatic-predominant-organ-failures-at-6-months-100613762","NCT07270809","To Study the Clinical Course and Outcomes of Non-electively Hospitalised Patients of Chronic Liver Disease (CLD) With Hepatic or Extra-hepatic Predominant Organ Failure(s) at 6 Months.","Inclusion Criteria:\n\n1. Age 18-70 years\n2. CLD with or without cirrhosis with 1st or subsequent admissions for decompenasation and irrespective of any prior decompensation\n3. Non-electively hospitalized\n\nExclusion Criteria:\n\n1. HCC\n2. NCPF\u002FEHPVO\n3. Pregnancy\n4. Post-Liver transplant",{"count":155,"type":21},100,"OBSERVATIONAL","Title - To study the clinical course and outcomes of non-electively hospitalised patients of chronic liver disease (CLD) with Hepatic or Extra-hepatic predominant organ failure(s) at 6 months.\n\nSummary - ACLF is a condition where acute insult leading to worsening liver failure with or without extra-hepatic failure leads to a high short-term mortality. However, the presence of cirrhosis, prior decompensation, non-hepatic\u002Fsystemic acute insult, organ failure and treatment are different in different part of the world. This is due to in-homogenous patient cohort. The current study was planned for all patients of CLD, who were non-electively hospitalized and were followed up for long-term to identify the differences in clinical course, acute insult, organ failure, therapy and outcome in relation to liver failure with or without extra-hepatic organic failure. In the study the laboratory, clinical parameters, inflammatory and regenerative markers will be evaluated as a marker of disease progression, reversal, recompensation or regression. This will enable us to differentiate the ACLF between east and west, guide us for defining the natural course of CLD with failure.",[27],"2025-11-26",{"date":161,"type":32},"2025-12-08",{"date":163,"type":21},"2025-11-30",{"date":165,"type":21},"2026-12-31",{"name":38,"class":39},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":40},"100607694","measuring-patient-reported-needs-in-outpatient-liver-disease-management-100607694","NCT07191886","Measuring Patient Reported Needs in Outpatient Liver Disease Management","Inclusion Criteria:\n\n* Patient Inclusion criteria\n\n  * Age 18 or greater\n  * English speaking\n  * Ability to give consent (West Haven stage 0-1 if history of hepatic encephalopathy)\n\nProvider Inclusion Criteria • Participated in patient care during inclusion visit\n\nExclusion Criteria:\n\n* Patient Exclusion criteria\n\n  * History of liver transplant\n  * Individuals not willing to participate in the survey\n  * Patients with severe cognitive impairment\n\nProvider Exclusion Criteria\n\n• Unable to complete survey within 7 days of the inclusion visit",{"count":174,"type":21},400,"This prospective study aims to assess health-related social needs (HRSNs) among patients with chronic liver disease (CLD) receiving outpatient care at Indiana University Health. Patients with CLD often face socioeconomic challenges that adversely affect health outcomes, but no validated screening tool exists for this population. The primary objective is to measure the prevalence and types of HRSNs in CLD patients. Secondary objectives are to evaluate patient preferences regarding provider involvement in addressing social needs, explore reasons for declining assistance, and assess provider perspectives on incorporating HRSN data into clinical care.\n\nA total of 200 adult patients with CLD and their visit providers will be enrolled. Participants will complete surveys on demographics, HRSNs, health literacy, quality of life, social support, and patient activation, with medical data supplemented from chart review. Providers will complete surveys about their experiences using HRSN data in routine practice. Results will describe unmet social needs in this population, patient and provider attitudes toward screening, and inform strategies for integrating HRSN assessments into liver disease management and routine healthcare delivery.",[27,177],"Cirrhosis, Liver",[179,180,181,182],"health-related social needs","social determinants of health","patient-reported outcomes","quality of life","2025-09-24",{"date":185,"type":32},"2025-09-29",{"date":187,"type":32},"2024-03-05",{"date":189,"type":21},"2027-05-30",{"name":191,"class":39},"Indiana University",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":202,"conditions":203,"keywords":207,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":221},"100561642","endoscopic-ultrasound-shear-wave-elastography-study-100561642","NCT06592820","Endoscopic Ultrasound Shear Wave Elastography Study","Endoscopic Ultrasound With Shear Wave Elastography for the Assessment of Liver Disease","EUS-SWE","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Willing and able to provide informed consent\n3. Patient scheduled to undergo EUS with liver biopsy, either same session or separately; if separate, liver biopsy should be performed within 3 months of the EUS (either before or after) with no interval bariatric procedure\u002Fsurgery or weight change of \\>10% total body weight\n4. Patient scheduled to undergo or have undergone FibroScan, which should be performed within 3 months of the EUS (either before or after) with no interval bariatric procedure\u002Fsurgery or weight change of \\>10% total body weight\n5. BMI \\>\u002F=28\n6. Clinical suspicion of MASLD (hepatic steatosis with at least one of five cardiometabolic risk factors: 1) overweight or obesity, 2) elevated glucose, 3) low HDL-C, 4) hypertension, and\u002For 5) hypertriglyceridemia) or MASH (additionally characterized by the presence of inflammation and hepatocellular ballooning) with or without fibrosis, as determined by non-invasive or minimally invasive techniques (e.g. abdominal ultrasound, FibroScan)\n\nExclusion Criteria:\n\n1. Patients with surgically altered anatomy that precludes adequate endosonographic visualization of the liver parenchyma\n2. Prior history of Hepatitis B or C infection\n3. Decompensated cirrhosis (GI bleeding, ascites, encephalopathy)\n4. Histological evidence of other concomitant chronic liver disease on biopsy\n5. Inadequate liver biopsy\n6. Prior history of or current excess alcohol consumption (\\>140 g\u002Fweek and \\>210 g\u002Fweek for females and males, respectively) documented in EMR",{"count":201,"type":21},300,"This study shall be a prospective, multicenter, single arm, consecutive, interventional study conducted in a post-market setting using commercially available devices. Consecutive, eligible patients with clinical suspicion of MASLD or MASH reporting for an endoscopic ultrasound and liver biopsy for evaluation of fibrosis will be enrolled. EUS Shear Wave Elastography and Attenuation Imaging technologies will be compared to liver biopsy and FibroScan results and other non-invasive fibrosis screening modalities . The data collected during this study will be evaluated in accordance with the procedures set forth in the protocol. The main question\\[s\\] it aims to answer are:\n\n* Establish optimal cutoffs for EUS-SWE in reference to liver biopsies staging system for liver fibrosis\n* Evaluate the diagnostic performance of EUS-SWE compared to FibroScan (VCTE) and to other non-invasive fibrosis screening modalities (screening scores).\n\nParticipants will undergo:\n\n* Endoscopic Ultrasound with Shear Wave Elastography (SWE) and Attenuation Imaging (ATI)\n* Liver biopsy\n* FibroScan",[204,205,206,27],"MASLD","MASH","Fibrosis, Liver",[208,209,210,211],"Shear Wave Elastography","Shear Wave","FibroScan","Attenuation Imaging","2025-09-11",{"date":214,"type":32},"2025-09-15",{"date":216,"type":32},"2025-09-03",{"date":218,"type":21},"2027-03-28",{"name":220,"class":147},"Olympus Corporation of the Americas",2,{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":231,"conditions":232,"keywords":235,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":40},"100549328","hepatomir-cacld-study-100549328","NCT06432582","hepatomiR cACLD Study","Assessment of a hepatomiR Cut-off for Predicting Specific Hepatic Decompensation Events in Advanced Chronic Liver Disease","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Chronic liver disease (more than 6 months)\n* LSM ≥ 10 kPa\n* Outpatient at the Clinical Department of Internal Medicine II, University Hospital St. Pölten\n* Signed patient consent form\n\nExclusion Criteria:\n\n* Age older than 18 years\n* Pregnancy\n* Primary hepatic malignancy (hepatocellular carcinoma, cholangiocarcinoma) with portal invasion and\u002For extrahepatic spread",{"count":230,"type":21},156,"This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.",[233,27,234],"Chronic Liver Disease and Cirrhosis","Portal Hypertension",[236,237,238,239],"hepatomiR","micro-RNA","hepatic decompensation","ACLD","2025-09-08",{"date":242,"type":32},"2025-09-09",{"date":244,"type":32},"2024-05-15",{"date":246,"type":21},"2026-06",{"name":248,"class":39},"Karl Landsteiner University of Health Sciences",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":256,"targetDuration":258,"studyType":156,"phases":4,"briefSummary":259,"conditions":260,"keywords":263,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":274,"locationsCount":276},"100528427","d-solve-cohorts-cohort-a-and-b-100528427","NCT06160635","D-SOLVE Cohorts (Cohort a and B)","HDV750","Inclusion Criteria:\n\n* Anti-HDV positive\n* ≥18 years old\n* Sex: m\u002Ff\u002Fd\n* Informed consent for prospective procedures\n\nExclusion Criteria:\n\n* Anti-HDV negative",{"count":257,"type":21},750,"3 Years","Hepatitis D is by far the most severe form of chronic viral hepatitis, frequently leading to liver failure, hepatocellular carcinoma and death. Hepatitis D is caused by coinfection Hepatitis D is caused by co-infection with hepatitis B virus (HBV) and hepatitis D virus (HDV).\n\nThis multicenter cohort should enable a comprehensive and unbiased biomarker screening of well-defined HDV-infected patients, followed by mechanistic studies to determine the functional role of distinct molecules. Patient surveillance strategies and antiviral treatment approaches could be personalized which should reduce clinical and social disease burden, improve quality of life and save direct and indirect costs caused by HDV infection.",[261,262,27],"HDV","HDV Infection",[261,264,265,266,267],"Hepatitis Delta","chronic liver disease","patient cohort","biomarker","2025-03-11",{"date":270,"type":32},"2025-03-12",{"date":272,"type":32},"2023-02-22",{"date":144,"type":21},{"name":275,"class":39},"Hannover Medical School",4,{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":40},"100573221","effect-of-perioperative-oral-rifaximin-on-early-graft-dysfunction-in-adult-living-donor-liver-transplant-100573221","NCT06743464","Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant","Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant: An Open Label Randomized Control Trial","Inclusion Criteria:\n\n* All recipients (adults) undergoing living donor liver transplant in ILBS.\n\nExclusion Criteria:\n\n* Negative consent\n\n  * Hypersensitivity to Rifaximin\n  * Patients undergoing retransplant\n  * ALF, ACLF\n  * Pediatrics patients\n  * Patients on rifaximin",{"count":155,"type":21},[24],"Liver transplantation has been a lifesaving treatment for individuals with end stage liver disease and acute liver failure. However, initial poor function of a liver allograft after liver transplantation, termed early graft dysfunction (EGD), has been associated with increased allograft loss or mortality after transplantation. EGD in LDLT is multifactorial. Factors affecting EGD are GRWR, ischemia reperfusion injury, recipient metabolic demand, graft quality, graft inflow and outflow. Studies shows that the incidence of EGD is 15-38%. It is associated with increased allograft loss \\& mortality. Rifaximin is an antibiotic that reduces EGD by 50% as shown by 2 studies but this study was done in DDLT setting and rifaximin was given in the pretransplant group.\n\nIn this investigators will study the effect of perioperative oral rifaximin on early graft dysfunction in adult living donor liver transplant.",[27],"2025-03-04",{"date":290,"type":32},"2025-03-05",{"date":292,"type":32},"2024-12-01",{"date":294,"type":21},"2025-12-31",{"name":38,"class":39},{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":321},"100540600","albumin-modifications-as-early-biomarkers-of-chronic-liver-diseases-100540600","NCT06318949","Albumin Modifications as Early Biomarkers of Chronic Liver Diseases","MALAHBAR","Inclusion Criteria:\n\n* At least 18 years old\n* With a compensated fibrosis defined by an hepatic elasticity ≥10 kPa measured by FibroScan®\n* Having had blood test at the hospital as part of a consultation or an hospitalisation at the inclusion including usual parameters for the liver disease follow-up\n* Affiliated with or beneficiaries of a social security system\n* Not opposed to participate to the study after being informed\n\nExclusion Criteria:\n\n* Patients suffering from decompensated cirrhosis or with an history of decompensated cirrhosis\n* Patients who received an albumin infusion in the month before the inclusion visit\n* Patients suffering from stage 4 or 5 renal failure (GFR \\\u003C 29 ml\u002Fmin\u002F1,73m²)\n* Patients suffering from cancer\n* Pregnant or breastfeeding women or women of childbearing age without effective contraception (based on declaration)\n* Patients suffering from impairment of mental faculties or a psychiatric disorder which could interfere with the understanding of the study",{"count":304,"type":21},756,[24],"Chronic liver diseases, affecting over 800 million people worldwide, lead to approximately 2 million annual deaths. The need for early, sensitive diagnostic strategies to prevent disease progression and reduce mortality is still unmet. The traditional serum markers lack sensitivity and specificity, leading to the integration of these biomarkers into panel tests with algorithms or imaging measures. Despite their widespread use, these tests have limitations at an individual level, including an inability to predict disease progression or response to treatment. To address these shortcomings, our project proposes utilizing albumin post-translational modifications (PTM) as a predictive biomarker for liver disease progression. The hypothesis is that albumin modifications occur in the early stages of hepatocellular damage and are indicative of future liver diseases. These modifications can be detected through serum albumin isoform determination, albumin isoforms profiles or the albumin's ligand-binding capacities. Innovatively, the study will use the Serum Enhanced Binding (SEB) test, which identifies reduced ligand-binding capacities, and discusses a second patent for determining a typical isoform profile based on the hepatic injury type.\n\nOur preliminary results from animal models and a proof-of-concept studies with patients support this hypotheses. Our previous studies demonstrated also significant differences in albumin isoform profiles in response to different types of hepatic injury and high sensitivity and specificity in the SEB test among cirrhotic patients.\n\nThe primary objective of the MALAHBAR project is to evaluate the capacity of albumin PTM to predict liver disease progression over three years in chronic liver disease patients. Secondary objectives include assessing the predictive ability of different albumin isoforms and the SEB test for liver disease progression, evaluating diagnostic performances and confirming characteristic albumin isoform profiles related to specific hepatic injuries. The study could represent a significant advancement in liver disease diagnostics and management, offering new insights into the role of albumin in liver pathology.",[27],[309,310,311],"predictive early biomarkers","albumine modifications","liver damage","2025-02-10",{"date":314,"type":32},"2025-02-12",{"date":316,"type":32},"2024-12-09",{"date":318,"type":21},"2029-12-01",{"name":320,"class":39},"University Hospital, Limoges",7,{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":329,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":40},"100577339","phase-2-efficacy-of-plasmapheresis-in-patients-of-drug-induced-liver-injury-dili-with-underlying-chronic-liver-disease-100577339","NCT06797011","Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease","Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease: An Open Labelled RCT","Inclusion Criteria:\n\n1. Adults aged 18-75 years with previously known or unknown underlying CLD.\n2. Diagnosis of DILI based causality of assessment by RECAM.\n3. Severe DILI with bilirubin \\> 12mg\u002Fdl or INR\\>2, S.Bili \\>5 mg\u002Fdl.\n4. Consent to participate in the study (based on biopsy\u002Fimaging\u002For clinical criteria).\n\nExclusion Criteria:\n\n1. Active infection\n2. Contraindications to plasmapheresis (e.g., severe coagulopathy, hemodynamic instability, patients with sepsis, shock, poor P\u002FF ratio).\n3. Pregnant or breastfeeding women.\n4. HCC or any malignancy\n5. UGI bleed, uncontrolled HE\n6. Option LTx being considered\n7. S. Creatinine \\> 2mg\u002FdL\n8. DILI ALF\n9. Alcoholic Hepatitis","75 Years",{"count":331,"type":21},96,[333,135],"PHASE2","DILI is an underdiagnosed and under appreciated causal or contributing factor to liver injury. DILI can mimics features of the entire spectrum of acute and chronic liver disease.\n\nAsia-Pacifc region is characterized by two unique features; the high prevalence of tuberculosis (TB) in the population and the ubiquitous use of traditional and complimentary medicines.Current definition of Hy's law presents significant difficulties when dealing with patients with preexisting CLD in clinical trials. Hallmark of the hepatic manifestation in these patients is hyperbilirubinemia and coagulopathy rather than ALT elevation.",[336,27],"Drug Induced Liver Injury","2025-01-27",{"date":339,"type":32},"2025-01-28",{"date":341,"type":21},"2025-01-25",{"date":343,"type":21},"2026-01-31",{"name":38,"class":39},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":22,"phases":353,"briefSummary":355,"conditions":356,"keywords":358,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":40},"100407642","phase-4-comparison-between-2-dose-versus-3-dose-regimens-of-heplisav-b-in-cirrhosis-100407642","NCT04588077","Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis","Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.","Inclusion Criteria:\n\n\\- All the cirrhosis patients more than 18 years old presented to the hepatology clinic in Mercy Medical Center between 09\u002F2020 and 07\u002F2021 who do not have immunity against Hepatitis B (defined as anti-HBs titer \\\u003C 10 mIU\u002Fml) will be recruited.\n\nExclusion Criteria:\n\n* Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine.\n* Those who had previous exposure to hepatitis B.\n* Post liver transplant patients.\n* Less than 18 years old.",{"count":51,"type":21},[354],"PHASE4","Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.",[357,177,27],"Hepatitis B",[359,360,82,265,361,362,363,364,365],"hepatitis B vaccine","Heplisav-B","2 dose regimen","3 dose regimen","non responder","poor responder","no response","2024-11-18",{"date":368,"type":32},"2024-11-19",{"date":370,"type":32},"2020-09-14",{"date":372,"type":21},"2028-12-01",{"name":374,"class":39},"Mercy Medical Center",{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":40},"100463296","evaluating-the-diagnostic-and-predictive-value-of-non-invasive-tests-nits-on-the-progression-of-chronic-liver-disease-100463296","NCT05312853","Evaluating the Diagnostic and Predictive Value of Non-invasive Tests (NITs) on the Progression of Chronic Liver Disease.","NITOutcomes","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Clinically suspected chronic liver disease based on any of:\n\n   1. Patient with historical liver biopsy providing histological evidence of any liver disease or,\n   2. Patient undergoing liver biopsy for suspected chronic liver disease with biochemical and\u002For radiological findings consistent with liver disease or,\n   3. Patient with clinical and radiological evidence of cirrhosis (in absence of an alternative aetiology)\n   4. Patients with metabolic risk factors predisposing to CLD\n\nExclusion Criteria:\n\n1. Refusal or inability (lack of capacity) to give informed consent.\n2. Age \\\u003C 18 years\n3. Pregnancy\n4. An active malignancy.\n5. Life expectation of \\\u003C 5 years.\n6. Patients not meeting inclusion criteria or judged by the investigator to be unsuitable for inclusion in the study.","99 Years",{"count":384,"type":21},250,"Primary objective is to study the relevance of non-invasive test (NITs) in predicting disease stage (diagnostic biomarker) and outcome (predictive biomarker) in patients with suspected or established liver disease and cirrhosis.",[27],"2023-12-27",{"date":389,"type":32},"2024-01-03",{"date":391,"type":21},"2024-01-15",{"date":393,"type":21},"2034-12-31",{"name":395,"class":39},"Johannes Gutenberg University Mainz",{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":406,"conditions":407,"keywords":408,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":40},"100213821","prognosis-value-of-non-invasive-methods-for-the-diagnosis-of-chronic-liver-disease-100213821","NCT02060565","Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease","Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease. a Retrospective and Prospective 20-year Follow-up.","PVNIM","Inclusion Criteria:\n\n* chronic hepatitis C\n* chronic hepatitis B\n* alcohol liver disease\n* non alcoholic liver disease\n\nExclusion Criteria:\n\n* ascitis",{"count":405,"type":21},10000,"The aim of this retrospective and prospective study is to evaluate the 20-year prognosis value of non-invasive methods for the diagnosis of chronic liver disease for predicting survival and complications of cirrhosis.",[27],[409,410,411,82,210],"diagnosis","survival","non-invasive method","2023-07-19",{"date":414,"type":32},"2023-07-20",{"date":416,"type":32},"2014-02",{"date":418,"type":21},"2034-02",{"name":420,"class":39},"Association HGE CHU Bordeaux Sud",{"id":422,"slug":423,"hasResults":11,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":429,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":432,"conditions":433,"keywords":434,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":40},"100465046","an-observational-study-evaluating-patients-with-chronic-liver-diseases-associated-with-hepatic-steatosis-100465046","NCT05335603","An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis","Fatty Liver Library (FALL): a Prospective Cohort Study Evaluating the Characteristics of Chronic Liver Diseases Associated With Hepatic Steatosis","FALL","Inclusion Criteria:\n\n* Adult patients\u002Fhealthy control participants (age 18 or above) who can give their informed consent\n* Suspected liver disease:\n* non-alcoholic steatohepatitis\n* alcoholic steatohepatitis\n* autoimmune hepatitis\n* primary biliary cholangitis\n* primary sclerosing cholangitis\n* inflammatory bowel disease\n* polycystic ovary syndrome\n* hereditary haemochromatosis\n* chronic pancreatitis\n* cystic fibrosis\n* alpha-1 antitrypsin deficiency\n\nExclusion Criteria:\n\nPatients with:\n\n* malignant diseases\n* viral hepatitis\n* human immunodeficiency virus\n* contraindications to liver biopsy",true,{"count":431,"type":21},335,"Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hereditary hemochromatosis and alpha-1-antitrypsin deficiency and may also develop secondary to other diseases like inflammatory bowel disease and chronic pancreatitis. Diagnosing chronic liver diseases can be challenging and treatment may be limited. In-depth phenotyping at a tissue level may generate insight into the underlying pathophysiology of diseases and furthermore identify common as well as specific diagnostic biomarkers and future treatment targets of the diseases. We therefore undertake a study that evaluates patients with chronic liver diseases associated with hepatic steatosis.",[27],[435,436,437,438,439,440,441,442,443,265,444,445,446],"non-alcoholic fatty liver disease","non-alcoholic steatohepatitis","steatosis","autoimmune hepatitis","primary biliary cholangitis","primary sclerosing cholangitis","haemochromatosis","alfa-1-antitrypsin deficiency","chronic pancreatitis","inflammatory bowel disease","OMICS","Mass spectrometry","2022-04-12",{"date":449,"type":32},"2022-04-19",{"date":451,"type":32},"2020-08-24",{"date":453,"type":21},"2036-08",{"name":455,"class":39},"University of Copenhagen",{"id":457,"slug":458,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":463,"targetDuration":465,"studyType":156,"phases":4,"briefSummary":466,"conditions":467,"keywords":472,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":40},"100212085","nottingham-community-liver-biomarkers-cohort-100212085","NCT02037867","Nottingham Community Liver Biomarkers Cohort","The Stratification of Liver Disease in the Community Using Fibrosis Biomarkers","Inclusion Criteria:\n\n* Adult patients aged 18 years or over (male or female) with primary risk factor for liver disease:\n\n  * Hazardous alcohol use (\\>14 units\u002Fweek for women, \\>21 units\u002Fweek for men)\n  * Type 2 Diabetes\n  * Obesity\n  * Persistently elevated ALT with normal liver serology\n\nExclusion Criteria:\n\n* Active malignancy at study enrolment\n* Inability to provide informed consent for study enrolment\n* Known presence of histologically proven liver disease prior to pilot pathway participation",{"count":464,"type":21},2000,"20 Years","Deaths due to advanced liver scarring (liver cirrhosis) continue to increase, and liver disease is now the 3rd leading cause of premature death in the United Kingdom. The majority of liver disease is lifestyle related (alcohol, obesity and associated type 2 diabetes, injecting drug use) and therefore reversible if caught at a precirrhosis stage. However, current liver function blood tests are poor inadequate, and subsequently a large burden of liver disease is currently missed.\n\nA variety of noninvasive liver biomarkers (blood and imaging tests) have been developed which identify liver disease accurately at earlier stages of scarring. The identification of liver disease in the community, where previous studies have discovered a large burden of previously unidentified but significant liver disease, is therefore a feasible place to develop new liver disease investigation pathways using these noninvasive markers.\n\nIn collaboration with the Department of Health, Nottingham University Hospitals have commenced a pilot community liver disease pathway in two General Practices in Nottingham in February 2012. Patients with liver risk factors (hazardous alcohol use, obesity or type 2 diabetes)are invited to take part in the pathway. Patients undergo a simple blood test (AST:ALT ratio and BARD score), with a high test result requiring referral for a liver stiffness scan (Fibroscan)which is performed in the community setting. High threshold scan values are reviewed by a consultant liver specialist in a community liver clinic. Preliminary findings show that the pathway accurately identifies patients with early liver scarring and previously unidentified significant liver disease. The participating General Practitioners have also noted a striking number of patients finally engaging in important lifestyle changes following pathway implementation. A second phase of the pilot pathway, in 2 Inner City General Practices with a total practice population of c.14,000 patients commenced in June 2013.\n\nWe have subsequently designed this cohort study, where pilot participants will be consented for follow up over a long period. We will assess future liver-related and cardiovascular events (including death), and perform qualitative patient interviews to assess the reasons for and persistence of lifestyle changes after liver disease investigation. We hypothesize that stratification of liver disease in the community will unearth a significant amount of previously undetected but significant chronic liver disease. Moreover, we will evaluate whether stratification of liver disease using these tests predicts future liver and cardiovascular disease and death, and whether stratification has an impact on patient's future lifestyle choices.",[27,468,469,470,471],"Alcohol Use Disorder","Type 2 Diabetes","Persistently Elevated ALT","Obesity",[473,474,475,476,477,82],"alcohol","type 2 diabetes","ALT","abnormal liver enzymes","hepatic fibrosis","2019-02-07",{"date":480,"type":32},"2019-02-08",{"date":482,"type":4},"2013-05",{"date":484,"type":21},"2033-05",{"name":486,"class":39},"University of Nottingham"]